NAFLD and extrahepatic cancers: Have a look at the colon

Gut

Volumn 60, Issue 6, 2011, Pages 745-746

  Tilg, Herbert ^a   Diehl, Anna Mae ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LEPTIN;

APOPTOSIS; CANCER CELL; CANCER RISK; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; COLORECTAL ADENOMA; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; ENDOTHELIUM CELL; EXTRAHEPATIC CANCER; FATTY LIVER; GROWTH INHIBITION; LIVER CANCER; NONALCOHOLIC FATTY LIVER; NOTE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; FATTY LIVER; HUMANS; LIVER NEOPLASMS;

EID: 79955860802     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2011.239392     Document Type: Note

References (20)

1. Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med 2010;363:2211-19.
2. Donohoe CL, Pidgeon GP, Lysaght J, et al. Obesity and gastrointestinal cancer. Br J Surg 2010;97:628-42.
3. Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev 2007;16:2533-47. (Pubitemid 351196307)
4. Morois S, Mesrine S, Josset M, et al. Anthropometric factors in adulthood and risk of colorectal adenomas: The French E3N-EPIC prospective cohort. Am J Epidemiol 2010;172:1166-80.
5. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467-76.
6. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-50.
7. Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut 2010;59:1303-7.
8. Musso G, Gambino R, Cassader M, et al. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. Published Online First: 2 November 2010. PMID: 21039302.
9. Bilici A, Ozguroglu M, Mihmanli I, et al. A case-control study of non-alcoholic fatty liver disease in breast cancer. Med Oncol 2007;24:367-71. (Pubitemid 350135927)
10. Hwang ST, Cho YK, Park JH, et al. Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps. J Gastroenterol Hepatol 2010;25:562-7.
11. Wong VW, Wong GL, Tsang SW, et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut 2011;60:829-36.
12. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-83. (Pubitemid 44453463)
13. Unger RH, Scherer PE. Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab 2010;21:345-52.
14. Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004;40:46-54.
15. Wei EK, Giovannucci E, Fuchs CS, et al. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 2005;97:1688-94. (Pubitemid 41672235)
16. Yamaji T, Iwasaki M, Sasazuki S, et al. Interaction between adiponectin and leptin influences the risk of colorectal adenoma. Cancer Res 2010;70:5430-7.
17. Kim AY, Lee YS, Kim KH, et al. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol 2010;24:1441-52.
18. Brakenhielm E, Veitonmaki N, Cao R, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 2004;101:2476-81. (Pubitemid 38269336)
19. Procaccini C, Galgani M, De Rosa V, et al. Leptin: the prototypic adipocytokine and its role in NAFLD. Curr Pharm Des 2010;16:1902-12.
20. Hong SN, Kim JH, Choe WH, et al. Prevalence and risk of colorectal neoplasms in asymptomatic, average-risk screenees 40 to 49 years of age. Gastrointest Endosc 2010;72:480-9.